临床相关性：treat
A total of 146 records found
#22233
high Confidence
Subject:
HPD
(protein)
→
is_potential_therapeutic_target_for
→
Object:
breast_cancer
(Malignant tumors)
Original: HPD#is a potential therapeutic target for#patients with breast cancer
#22183
high Confidence
Subject:
BRAF_rearrangement
(Gene rearrangement)
→
is_targetable_alteration_in
→
Object:
acinar_carcinoma
(Tumor type)
Original: Targetable molecular alterations in acinar carcinoma#include#BRAF rearrangements and DNA repair defects
#22125
high Confidence
Subject:
CTLA-4_inhibitor
(Immune checkpoint inhibitors)
→
produces
→
Object:
significant_clinical_response
(Clinical response)
Original: Immunotherapy with PD-1/PD-L1/CTLA-4 inhibitors#produced#significant clinical responses
#22124
high Confidence
Subject:
PD-L1_inhibitor
(Immune checkpoint inhibitors)
→
produces
→
Object:
significant_clinical_response
(Clinical response)
Original: Immunotherapy with PD-1/PD-L1/CTLA-4 inhibitors#produced#significant clinical responses
#22123
high Confidence
Subject:
PD-1_inhibitor
(Immune checkpoint inhibitors)
→
produces
→
Object:
significant_clinical_response
(Clinical response)
Original: Immunotherapy with PD-1/PD-L1/CTLA-4 inhibitors#produced#significant clinical responses
#22055
high Confidence
Subject:
complete_surgical_excision
(Treatment procedures)
→
provides
→
Object:
disease-free_survival
(Clinical Outcomes)
Original: complete surgical excision#provides#the best chance for disease-free survival
#22042
high Confidence
Subject:
surgery
(Surgery)
→
removes
→
Object:
cystic_calculi
(Disease phenotype)
Original: Surgery#was done to remove#cystic calculi
#22022
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
postoperative_left_vulvar_irradiation
(Radiation therapy)
Original: Patient#underwent#a left radical vulvectomy with bilateral inguinal and pelvic lymphadenectomy and postoperative left vulvar irradiation
#22021
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
pelvic_lymphadenectomy
(Surgery)
Original: Patient#underwent#a left radical vulvectomy with bilateral inguinal and pelvic lymphadenectomy and postoperative left vulvar irradiation
#22020
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
bilateral_inguinal_lymphadenectomy
(Surgery)
Original: Patient#underwent#a left radical vulvectomy with bilateral inguinal and pelvic lymphadenectomy and postoperative left vulvar irradiation
#22019
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
left_radical_vulvectomy
(Surgery)
Original: Patient#underwent#a left radical vulvectomy with bilateral inguinal and pelvic lymphadenectomy and postoperative left vulvar irradiation
#21986
high Confidence
Subject:
surgical_excision
(Treatment)
→
is_recommended_for
→
Object:
tumor-free_margins
(Treatment goals)
Original: surgical excision#is recommended for#tumor-free margins and prolonged follow-up
#21899
high Confidence
Subject:
DNA_repair_defect
(DNA repair defects)
→
is_targetable_alteration_in
→
Object:
acinar_carcinoma
(Tumor type)
Original: Targetable molecular alterations in acinar carcinoma#include#BRAF rearrangements and DNA repair defects
#21637
high Confidence
Subject:
EGFR
(Receptor protein)
→
inhibition_of
→
Object:
tumor_growth
(Tumor growth process)
Original: Reduction in EGF receptors#inhibits#tumor growth
#21592
high Confidence
Subject:
ALK_phosphorylation
(Protein kinase modification)
→
drives
→
Object:
systemic_ALCL_pathogenesis
(Disease progression)
Original: Phosphorylation of ALK tyrosine kinase#drives#systemic ALCL pathogenesis
#21564
high Confidence
Subject:
ribosome_biogenesis
(Ribosome biogenesis)
→
disruption_kills
→
Object:
tumor_cells
(cancer cell)
Original: Disruption of ribosome biogenesis#kills#tumor cells via nucleolar function disruption
#21539
high Confidence
Subject:
grading_of_breast_carcinoma
(Tumor grade)
→
is_helpful_in
→
Object:
selection_of_patients_for_appropriate_therapy
(Treatment options)
Original: grading of breast carcinoma#is helpful in#selecting patients for appropriate therapy
#21502
high Confidence
Subject:
tumor
(Tumor)
→
was_curatively_resected_by
→
Object:
surgery
(Surgery)
Original: The tumor#was curatively resected#via surgery
#21295
high Confidence
Subject:
Extended_thymectomy
(Treatment)
→
should_be_performed_for
→
Object:
thymoma
(Tumor type)
Original: Extended thymectomy#should be performed for#thymoma to prevent recurrence
#21005
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
chemotherapy
(Treatment)
Original: Patient#underwent#radiation (50 Gray) and chemotherapy (cisplatin/ 5 courses)
#21004
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
radiation_therapy
(Treatment)
Original: Patient#underwent#radiation (50 Gray) and chemotherapy (cisplatin/ 5 courses)
#20712
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
sentinel_lymph_node_biopsy
(Type of surgery)
Original: Patient#underwent#simple mastectomy and sentinel lymph node biopsy
#20711
high Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
simple_mastectomy
(Type of surgery)
Original: Patient#underwent#simple mastectomy and sentinel lymph node biopsy
#20427
high Confidence
Subject:
STAT5
(Transcription Factors)
→
is_involved_in
→
Object:
JAK/STAT_pathway
(signaling pathway)
Original: Signal transduction pathways#involve#PI3K/Akt/ STAT3/ and STAT5 proteins
#20426
high Confidence
Subject:
STAT3
(Transcription Factors)
→
is_involved_in
→
Object:
JAK/STAT_pathway
(signaling pathway)
Original: Signal transduction pathways#involve#PI3K/Akt/ STAT3/ and STAT5 proteins
#20425
high Confidence
Subject:
AKT1
(Protein kinase)
→
is_involved_in
→
Object:
PI3K/AKT_pathway
(signaling pathway)
Original: Signal transduction pathways#involve#PI3K/Akt/ STAT3/ and STAT5 proteins
#20424
high Confidence
Subject:
PIK3CA
(Protein kinase)
→
is_involved_in
→
Object:
PI3K/AKT_pathway
(signaling pathway)
Original: Signal transduction pathways#involve#PI3K/Akt/ STAT3/ and STAT5 proteins
#20359
high Confidence
Subject:
HPSE
(Hydrolases)
→
correlates_with
→
Object:
angiogenesis
(Angiogenesis)
Original: Heparanase#correlates with#angiogenesis
#20236
high Confidence
Subject:
Children's Cancer Group ALL protocols
(Treatment options)
→
treats
→
Object:
Acute lymphoblastic leukemia
(disease)
Original: Both patients#were treated with#Children's Cancer Group ALL protocols
#20087
high Confidence
Subject:
targeted_therapeutics
(Targeted therapy drugs)
→
interrupt
→
Object:
bone_degradation
(Bone degradation process)
Original: targeted therapeutics#interrupt#cycle of tumor development and bone degradation
#20086
high Confidence
Subject:
targeted_therapeutics
(Targeted therapy drugs)
→
interrupt
→
Object:
tumor_development
(Tumor development process)
Original: targeted therapeutics#interrupt#cycle of tumor development and bone degradation
#19948
middle Confidence
Subject:
toceranib
(Targeted drugs)
→
inhibited
→
Object:
enlargement_of_lesion
(Disease progression)
Original: Toceranib#inhibited#enlargement of the lesion
#19925
middle Confidence
Subject:
vemurafenib
(Targeted drugs)
→
is_considered_for
→
Object:
treatment_of_histiocytic_sarcoma
(Treatment Process)
Original: vemurafenib#is considered for#treatment of histiocytic sarcoma
#19923
middle Confidence
Subject:
375_prostatic_carcinoma_patients
(patient)
→
were_treated_with
→
Object:
radiation_therapy
(Radiation therapy)
Original: 375 prostatic carcinoma patients#were treated with#radiation therapy
#19876
middle Confidence
Subject:
PD-MSCs
(Mesenchymal stem cells)
→
repair
→
Object:
hippocampal_neurons_with_HI_injury
(Neurons)
Original: PD-MSCs#repair#morphology and function of hippocampal neurons with HI injury
#19875
middle Confidence
Subject:
PD-MSCs
(Mesenchymal stem cells)
→
show_therapeutic_efficacy
→
Object:
HIE_rat_model
(Animal models)
Original: PD-MSCs#show#therapeutic efficacy in HIE rat model
#19859
middle Confidence
Subject:
curcumin
(Curcumin)
→
decreases_expression_of
→
Object:
nucleolar_organizer_regions
(Nucleolar organizing region)
Original: Curcumin#decreased expression of#nucleolar organizer regions in cervical cancer cells
#19791
middle Confidence
Subject:
progestin
(Hormonal drugs)
→
reduces
→
Object:
cell_proliferation
(Cellular Processes)
Original: Progestins#act by#differentiation of neoplastic cells with diminished proliferation
#19790
middle Confidence
Subject:
progestin
(Hormonal drugs)
→
induces
→
Object:
differentiation_of_neoplastic_cell
(Cellular Processes)
Original: Progestins#act by#differentiation of neoplastic cells with diminished proliferation
#19661
middle Confidence
Subject:
whole_brain_radiation_therapy
(Treatment)
→
succeeded_in
→
Object:
tumor_residual_control
(Disease process)
Original: Whole-brain radiation therapy#succeeded in#controlling the residual tumor
#19629
middle Confidence
Subject:
R-THP-COP_therapy
(Chemotherapy regimen)
→
achieves
→
Object:
complete_remission
(Clinical Outcomes)
Original: R-THP-COP therapy#achieves#complete remission (CR)
#19436
middle Confidence
Subject:
preoperative_diagnosis_of_CZ_PAC
(Diagnostic behavior)
→
can_improve
→
Object:
surgical_resection_rate
(Surgical resection rate)
Original: Preoperative diagnosis of CZ PAC#can improve#surgical resection rate
#19370
middle Confidence
Subject:
radiation_therapy
(Radiation therapy)
→
is_curative_for
→
Object:
tumor
(Tumor type)
Original: Radiation therapy#has been#curative in at least two cases
#19299
middle Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
right_axillary_lymphadenectomy
(Surgical treatment)
Original: Patient#underwent#partial resection of the right breast and right axillary lymphadenectomy
#19298
middle Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
partial_resection_of_right_breast
(Surgical treatment)
Original: Patient#underwent#partial resection of the right breast and right axillary lymphadenectomy
#19227
middle Confidence
Subject:
NAT10
(protein)
→
may_be
→
Object:
potential_therapeutic_target
(Therapeutic targets)
Original: NAT10#may be#a prognostic marker and potential therapeutic target
#19224
middle Confidence
Subject:
PAX2
(Transcription Factors)
→
downregulation_abrogated
→
Object:
chemoresistance_in_melanoma_cells
(Drug resistance)
Original: downregulation of PAX2#abrogated#chemoresistance in melanoma cells
#19179
middle Confidence
Subject:
monoclonal_antibodies
(Monoclonal antibodies)
→
interfere_with
→
Object:
tumor-induced_bone_alterations
(Bone changes)
Original: small molecule inhibitors and monoclonal antibodies#interfere with#tumor-induced alterations in bone
#19178
middle Confidence
Subject:
small_molecule_inhibitors
(Small molecule inhibitors)
→
interfere_with
→
Object:
tumor-induced_bone_alterations
(Bone changes)
Original: small molecule inhibitors and monoclonal antibodies#interfere with#tumor-induced alterations in bone
#19005
middle Confidence
Subject:
ribosome_biogenesis
(Molecular Process)
→
activates
→
Object:
p53
(Tumor suppressor proteins)
Original: Targeting ribosome biogenesis#activates#p53 as a therapeutic strategy in human cancer
#18958
middle Confidence
Subject:
HPSE
(Protease)
→
is_target_of
→
Object:
anticancer_therapeutics
(Anticancer drugs)
Original: Heparanase#is a target for#anticancer therapeutics
#18872
middle Confidence
Subject:
Hesperetin
(Natural small molecule compounds)
→
inhibits
→
Object:
PCNA
(Proliferation-related proteins)
Original: Hesperetin#exhibits antiproliferative effects on#aberrant crypt foci (ACF)/ AgNORs/ and PCNA in DMH-induced colon carcinogenesis
#18871
middle Confidence
Subject:
Hesperetin
(Natural small molecule compounds)
→
inhibits
→
Object:
AgNORs
(Nucleolar Organizing Region Marker)
Original: Hesperetin#exhibits antiproliferative effects on#aberrant crypt foci (ACF)/ AgNORs/ and PCNA in DMH-induced colon carcinogenesis
#18870
middle Confidence
Subject:
Hesperetin
(Natural small molecule compounds)
→
inhibits
→
Object:
aberrant_crypt_foci
(Pathological structure)
Original: Hesperetin#exhibits antiproliferative effects on#aberrant crypt foci (ACF)/ AgNORs/ and PCNA in DMH-induced colon carcinogenesis
#18831
middle Confidence
Subject:
allogeneic_BMT
(Hematopoietic stem cell transplantation)
→
performed_after
→
Object:
tumor_loading_reduction
(Tumor burden)
Original: Allogeneic BMT#was performed smoothly after#tumor loading was reduced
#18791
middle Confidence
Subject:
radical_nephrectomy
(Surgery)
→
was_performed_for
→
Object:
papillary_renal_cell_carcinoma
(Kidney tumors)
Original: A radical nephrectomy#was performed#for a large papillary renal cell carcinoma
#18495
middle Confidence
Subject:
surgical_excision
(Treatment)
→
is_recommended_for
→
Object:
prolonged_follow-up
(Follow-up goals)
Original: surgical excision#is recommended for#tumor-free margins and prolonged follow-up
#18435
middle Confidence
Subject:
pelvic_lymphadenectomy
(Surgery)
→
performed_on
→
Object:
patient_without_melanoma_history
(Patient characteristics)
Original: Partial cystectomy and pelvic lymphadenectomy#were performed on#a patient without melanoma history
#18434
middle Confidence
Subject:
partial_cystectomy
(Surgery)
→
performed_on
→
Object:
patient_without_melanoma_history
(Patient characteristics)
Original: Partial cystectomy and pelvic lymphadenectomy#were performed on#a patient without melanoma history
#18352
middle Confidence
Subject:
BR_therapy
(Chemotherapy regimen)
→
achieves
→
Object:
fourth_complete_remission
(Clinical Outcomes)
Original: BR therapy#achieves#fourth complete remission (CR)
#18350
middle Confidence
Subject:
surgery
(Treatment)
→
removes
→
Object:
ileum_origin_tumor
(Tumor)
Original: surgery#is scheduled for#removal of tumor originating in ileum
#18300
middle Confidence
Subject:
surgery
(Surgery)
→
treats
→
Object:
Tubular_adenocarcinoma
(Tumor type)
Original: 31 patients#underwent#surgery for very well differentiated tubular adenocarcinoma
#18299
middle Confidence
Subject:
Patients
(patient)
→
underwent
→
Object:
surgery
(Surgery)
Original: 31 patients#underwent#surgery for very well differentiated tubular adenocarcinoma
#18202
middle Confidence
Subject:
Uveal_melanoma_cases
(Tumor Cases)
→
were_treated_by
→
Object:
primary_transscleral_local_resection
(Treatment)
Original: Uveal melanoma cases#were treated by#primary transscleral local resection without primary adjuvant treatment
#18162
middle Confidence
Subject:
61-year-old_female_patient
(Patient characteristics)
→
underwent
→
Object:
endonasal_transsphenoidal_approach
(Surgery)
Original: 61-year-old female patient#underwent#endonasal transsphenoidal approach
#18149
middle Confidence
Subject:
Patient
(patient)
→
is_free_of_disease_after
→
Object:
total_excision_of_lesion
(Surgery)
Original: Patient#is free of disease after#total excision of the lesion
#17758
middle Confidence
Subject:
accurate_diagnosis
(Diagnostic behavior)
→
avoids
→
Object:
unnecessary_surgery
(Treatment)
Original: Accurate diagnosis#avoids#unnecessary surgery in cases of mediastinum metastasis
#17756
middle Confidence
Subject:
Patients
(patient)
→
received
→
Object:
autologous stem cell rescue
(Autologous stem cell rescue)
Original: Patients#were treated with#high-dose therapy and autologous stem cell rescue
#17755
middle Confidence
Subject:
Patients
(patient)
→
received
→
Object:
high-dose therapy
(High-dose therapy)
Original: Patients#were treated with#high-dose therapy and autologous stem cell rescue
#17318
middle Confidence
Subject:
tumor_cytological_features
(Tumor cytological characteristics)
→
contribute_to
→
Object:
early_treatment_intervention
(Therapeutic interventions)
Original: Understanding of tumor's cytological features#contributes to#early treatment intervention
#17220
middle Confidence
Subject:
Doxorubicin
(Chemotherapy drugs)
→
inhibits
→
Object:
cell_growth
(Cell proliferation)
Original: DOX#induces#nucleophosmin translocation from the nucleolus to nucleoplasm and inhibits cell growth in a time- and dose-dependent manner
#17218
middle Confidence
Subject:
Dipyridamole
(Chemotherapy drugs)
→
enhances
→
Object:
doxorubicin_sensitivity
(Drug sensitivity)
Original: Dipyridamole (DPM)#enhanced#sensitivity to doxorubicin (DOX) in a human leukemia cell line
#17157
middle Confidence
Subject:
therapeutic_approaches
(Treatment strategies)
→
focus_on
→
Object:
TGFβ/TGFβR_pathway
(signaling pathway)
Original: therapeutic approaches#focus on#VEGF/VEGFR/ EGF/EGFR/ FGF/FGFR/ TGFβ/TGFβR pathways
#17156
middle Confidence
Subject:
therapeutic_approaches
(Treatment strategies)
→
focus_on
→
Object:
FGF/FGFR_pathway
(signaling pathway)
Original: therapeutic approaches#focus on#VEGF/VEGFR/ EGF/EGFR/ FGF/FGFR/ TGFβ/TGFβR pathways
#17155
middle Confidence
Subject:
therapeutic_approaches
(Treatment strategies)
→
focus_on
→
Object:
EGF/EGFR_pathway
(signaling pathway)
Original: therapeutic approaches#focus on#VEGF/VEGFR/ EGF/EGFR/ FGF/FGFR/ TGFβ/TGFβR pathways
#17154
middle Confidence
Subject:
therapeutic_approaches
(Treatment strategies)
→
focus_on
→
Object:
VEGF/VEGFR_pathway
(signaling pathway)
Original: therapeutic approaches#focus on#VEGF/VEGFR/ EGF/EGFR/ FGF/FGFR/ TGFβ/TGFβR pathways
#16968
middle Confidence
Subject:
ActD
(Chemotherapy drugs)
→
could_improve
→
Object:
effect_of_standard_chemotherapy
(Treatment Effects)
Original: ActD#could improve#effect of standard chemotherapy in leukemias
#16967
middle Confidence
Subject:
low-dose_actD
(Chemotherapy drugs)
→
induces
→
Object:
cell_death_in_leukemic_cell_lines
(Cellular Processes)
Original: Low-dose actD#induces#cell death in leukemic cell lines
#16966
middle Confidence
Subject:
low-dose_actD
(Chemotherapy drugs)
→
induces
→
Object:
cell_death
(Cellular Processes)
Original: Low-dose actD#induces#cell death in leukemic cell lines
#16786
middle Confidence
Subject:
S9
(Small molecule drugs)
→
inhibits
→
Object:
cancer_cell_proliferation
(Cellular Processes)
Original: S9#inhibits#cancer cell proliferation in vitro and in vivo
#16777
middle Confidence
Subject:
PD-MSC_transplantation
(Cell therapy)
→
enhances
→
Object:
muscle_strength
(Motor function phenotype)
Original: PD-MSC transplantation#enhances#motor coordination and muscle strength in HIE rats
#16776
middle Confidence
Subject:
PD-MSC_transplantation
(Cell therapy)
→
enhances
→
Object:
motor_coordination
(Motor function phenotype)
Original: PD-MSC transplantation#enhances#motor coordination and muscle strength in HIE rats
#16722
middle Confidence
Subject:
cisplatin
(Small molecule drugs)
→
shows
→
Object:
antitumor_effect
(Drug effects)
Original: RAP#showed#antitumor effects similar to cisplatin but with lower cytotoxicity
#16721
middle Confidence
Subject:
RAP
(Small molecule drugs)
→
shows
→
Object:
antitumor_effect
(Drug effects)
Original: RAP#showed#antitumor effects similar to cisplatin but with lower cytotoxicity
#16716
middle Confidence
Subject:
calpain_3_variant
(Protein variants)
→
plays
→
Object:
proapoptotic_role
(Cellular process function)
Original: Calpain 3 variants#play#proapoptotic role in melanoma cells
#16709
middle Confidence
Subject:
oxaliplatin_treatment
(Chemotherapy drugs)
→
activates
→
Object:
Caspase
(Caspase)
Original: oxaliplatin treatment#activated#caspase
#16708
middle Confidence
Subject:
Oxaliplatin
(Chemotherapy drugs)
→
treats
→
Object:
CCRF_CEM_cells
(Leukemia cell lines)
Original: oxaliplatin#was used to treat#chemosensitive CCRF-CEM cells
#16559
middle Confidence
Subject:
SB-75
(Small molecule drugs)
→
reduces
→
Object:
AgNOR_number
(Number of nucleolar organizer region markers)
Original: SB-75 treatment#reduces#AgNOR number in Dunning R3327 rat prostate tumors
#16071
middle Confidence
Subject:
Zerumbone
(Natural Products)
→
affects
→
Object:
cell_proliferation_activity_of_colonic_crypts
(Cell proliferation process)
Original: Zerumbone#affects#cell proliferation activity of colonic crypts
#15637
middle Confidence
Subject:
Patient_1
(patient)
→
had
→
Object:
autologous_BMT
(Autologous bone marrow transplantation)
Original: Patient 1#had#autologous BMT
#15636
middle Confidence
Subject:
Patients
(patient)
→
received
→
Object:
polyregimen_chemotherapy_protocols
(Chemotherapy regimen)
Original: Patients#received#different polyregime chemotherapy protocols
#15474
middle Confidence
Subject:
complete_surgical_excision
(Treatment)
→
was_performed_with
→
Object:
frozen_section_margin_control
(Assistive Technology)
Original: Complete surgical excision#was performed#with a frozen section margin control
#15337
middle Confidence
Subject:
patient
(patient)
→
was_treated_with
→
Object:
prednisone
(Glucocorticoids)
Original: patient#was treated with#six cycles of cyclophosphamide/ doxorubicin/ vincristine and prednisone (CHOP)
#15336
middle Confidence
Subject:
patient
(patient)
→
was_treated_with
→
Object:
vincristine
(Chemotherapy drugs)
Original: patient#was treated with#six cycles of cyclophosphamide/ doxorubicin/ vincristine and prednisone (CHOP)
#15335
middle Confidence
Subject:
patient
(patient)
→
was_treated_with
→
Object:
doxorubicin
(Chemotherapy drugs)
Original: patient#was treated with#six cycles of cyclophosphamide/ doxorubicin/ vincristine and prednisone (CHOP)
#15334
middle Confidence
Subject:
patient
(patient)
→
was_treated_with
→
Object:
cyclophosphamide
(Chemotherapy drugs)
Original: patient#was treated with#six cycles of cyclophosphamide/ doxorubicin/ vincristine and prednisone (CHOP)
#15250
middle Confidence
Subject:
gross_total_surgical_excision
(Treatment)
→
was_performed_for
→
Object:
cerebellar_tumor
(disease)
Original: a six-year-old boy#underwent#gross total surgical excision of a cerebellar tumor
#15249
middle Confidence
Subject:
six-year-old_boy
(Patient characteristics)
→
underwent
→
Object:
gross_total_surgical_excision
(Treatment)
Original: a six-year-old boy#underwent#gross total surgical excision of a cerebellar tumor
#15130
middle Confidence
Subject:
total_gastrectomy
(Surgery)
→
was_performed_on
→
Object:
ulcerofungating_mass
(Tumor phenotype)
Original: Total gastrectomy#was performed on#ulcerofungating mass
#14236
middle Confidence
Subject:
Roux-en-Yé esophagojejunostomy
(Surgery)
→
performed_in
→
Object:
gastric_melanoma_patient
(Patient Entity)
Original: Patient#underwent#radical total gastrectomy/ pancreatic body and tail resection/ splenectomy/ and Roux-en-Y esophagojejunostomy
#14235
middle Confidence
Subject:
Splenectomy
(Surgery)
→
performed_in
→
Object:
gastric_melanoma_patient
(Patient Entity)
Original: Patient#underwent#radical total gastrectomy/ pancreatic body and tail resection/ splenectomy/ and Roux-en-Y esophagojejunostomy
#14234
middle Confidence
Subject:
pancreatic_body_and_tail_resection
(Surgery)
→
performed_in
→
Object:
gastric_melanoma_patient
(Patient Entity)
Original: Patient#underwent#radical total gastrectomy/ pancreatic body and tail resection/ splenectomy/ and Roux-en-Y esophagojejunostomy
#14233
middle Confidence
Subject:
radical_total_gastrectomy
(Surgery)
→
performed_in
→
Object:
gastric_melanoma_patient
(Patient Entity)
Original: Patient#underwent#radical total gastrectomy/ pancreatic body and tail resection/ splenectomy/ and Roux-en-Y esophagojejunostomy
#14131
middle Confidence
Subject:
31-year-old_woman
(Patient characteristics)
→
underwent
→
Object:
surgical_excision_for_polypoid_vulvar_lesion
(Treatment procedures)
Original: A 31-year-old woman#underwent#surgical excision for a polypoid vulvar lesion
#13903
middle Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
external_beam_irradiation
(Radiation therapy)
Original: patient#underwent#external beam irradiation for seminoma
#13902
middle Confidence
Subject:
patient
(patient)
→
received
→
Object:
corticosteroids
(Glucocorticoids)
Original: patient#received#corticosteroids for adrenocorticoid deficiency
#13420
middle Confidence
Subject:
total_parotidectomy
(Surgical treatment)
→
was_done_with
→
Object:
facial_nerve_preservation
(Surgical Procedure)
Original: Total parotidectomy#was done#with facial nerve preservation
#12552
middle Confidence
Subject:
growth_factor_receptors
(Receptor protein)
→
interact_with
→
Object:
bone_microenvironment
(Tissue Microenvironment)
Original: growth factor receptors#interact with#bone microenvironment
#12084
middle Confidence
Subject:
local_irradiation
(Treatment)
→
is_effective_treatment_for
→
Object:
Anaplastic_large_cell_lymphoma
(Tumor diseases)
Original: Excision or local irradiation#is effective treatment for#ALCL
#12083
middle Confidence
Subject:
Excision
(Treatment)
→
is_effective_treatment_for
→
Object:
Anaplastic_large_cell_lymphoma
(Tumor diseases)
Original: Excision or local irradiation#is effective treatment for#ALCL
#12029
middle Confidence
Subject:
RAP
(Small molecule drugs)
→
has_lower
→
Object:
cytotoxicity_than_cisplatin
(Drug toxicity)
Original: RAP#showed#antitumor effects similar to cisplatin but with lower cytotoxicity
#12011
middle Confidence
Subject:
Bleomycin
(Anticancer drugs)
→
treats
→
Object:
tongue_carcinoma
(Malignant tumors)
Original: Five patients with tongue carcinoma#were treated with#bleomycin
#12010
middle Confidence
Subject:
5-aminolevulinic_acid_based_PDT
(Photodynamic therapy)
→
affects
→
Object:
nucleoli_of_leukemic_granulocytic_precursors
(Nucleolus)
Original: 5-aminolevulinic acid-based photodynamic treatment#affects#nucleoli of leukemic granulocytic precursors
#11998
middle Confidence
Subject:
hepatocellular_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11997
middle Confidence
Subject:
gastric_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11996
middle Confidence
Subject:
pancreatic_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11995
middle Confidence
Subject:
biliary_tract_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11994
middle Confidence
Subject:
esophageal_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11993
middle Confidence
Subject:
hematological_cancer
(Tumor type)
→
is_treated_with
→
Object:
experimental_therapy
(Experimental treatments)
Original: hematological/ esophageal/ biliary tract/ pancreatic/ gastric/ and hepatocellular cancers#are being treated with#experimental therapies
#11802
middle Confidence
Subject:
CX
(Chemotherapy drugs)
→
decreases
→
Object:
AgNORs
(Nucleolar organizer region-associated protein)
Original: Treatment with AX or CX#decreased#the number/nucleus of silver-stained nucleolar organizer region proteins (AgNORs)
#11801
middle Confidence
Subject:
AX
(Chemotherapy drugs)
→
decreases
→
Object:
AgNORs
(Nucleolar organizer region-associated protein)
Original: Treatment with AX or CX#decreased#the number/nucleus of silver-stained nucleolar organizer region proteins (AgNORs)
#11545
middle Confidence
Subject:
new_biomarkers
(Biomarkers)
→
supports
→
Object:
targeted_therapy
(Treatment options)
Original: Screening new biomarkers#supports#early clinical diagnosis and targeted therapy of ccRCC
#11387
middle Confidence
Subject:
patient
(Patient characteristics)
→
received
→
Object:
radiotherapy
(Therapeutic interventions)
Original: the patient#received#radiotherapy after the surgery
#10730
middle Confidence
Subject:
MDK
(Growth Factors)
→
might_serve_as
→
Object:
molecular_target_for_therapeutic_intervention
(Therapeutic targets)
Original: MK#might serve as#a molecular target for therapeutic intervention of human carcinomas
#10726
middle Confidence
Subject:
poly(I)-poly(C)
(Synthetic dsRNA molecules)
→
exhibits
→
Object:
antitumor_effect
(Anti-tumor effect)
Original: poly(I)-poly(C)#exhibits#antitumor effect via mechanisms other than interferon or host-mediated immune enhancement
#10680
middle Confidence
Subject:
this_agent
(drug)
→
inhibits
→
Object:
growth_of_human_cancer_cell_lines
(Cell proliferation)
Original: this agent#inhibits#growth of human cancer cell lines
#10412
middle Confidence
Subject:
patient
(patient)
→
was_initially_treated_for
→
Object:
Hodgkin_disease
(Disease classification)
Original: Patient#was initially treated for#Hodgkin's disease
#9972
middle Confidence
Subject:
short_term_human_mammary_carcinoma_cells
(Tumor cells)
→
is_feasible_for
→
Object:
retroviral_mediated_cytokine_gene_transfer
(Gene transfer technology)
Original: Retroviral-mediated cytokine gene transfer#is feasible in#short-term human mammary carcinoma cells
#8904
middle Confidence
Subject:
treatment
(Treatment options)
→
followed_by
→
Object:
radiotherapy
(Treatment)
Original: Treatment#consisted of#surgical resection followed by radiotherapy
#8903
middle Confidence
Subject:
treatment
(Treatment options)
→
consisted_of
→
Object:
surgical_resection
(Treatment)
Original: Treatment#consisted of#surgical resection followed by radiotherapy
#8727
middle Confidence
Subject:
encapsulated_hard_mass
(Lump)
→
was_resected_en_bloc_ensuring
→
Object:
wide_resection_margins
(Surgical boundaries)
Original: Encapsulated hard mass#was resected en-bloc ensuring#wide resection margins
#7358
middle Confidence
Subject:
patients
(patient)
→
were_treated_with
→
Object:
surgery_alone
(Treatment options)
Original: patients#were treated with#surgery alone
#5108
middle Confidence
Subject:
patients
(patient)
→
are_treated_with
→
Object:
Lisurid
(drug)
Original: Patients#are treated with#bromocriptine and/or Lisurid
#5107
middle Confidence
Subject:
patients
(patient)
→
are_treated_with
→
Object:
Bromocriptine
(drug)
Original: Patients#are treated with#bromocriptine and/or Lisurid
#4717
middle Confidence
Subject:
Standard_treatment
(Treatment options)
→
has_not_been_established
→
Object:
Primary_small_cell_carcinoma_of_the_vagina
(disease)
Original: Standard treatment#has not been#established
#4440
low Confidence
Subject:
single_patient
(patient)
→
underwent
→
Object:
surgical_resection
(Surgery)
Original: a single patient#underwent#surgical resection
#4419
low Confidence
Subject:
patient
(patient)
→
was_treated_by
→
Object:
radical_nephrectomy
(Surgical treatment)
Original: All patients#were#male (median age/ 71 years)/ treated by radical nephrectomy and free of recurrence or metastasis (median follow-up/ 62 months)
#4200
low Confidence
Subject:
radical_hysterectomy
(Surgery)
→
was_performed_in
→
Object:
both_patients
(patient)
Original: Radical hysterectomy#was performed in#both patients
#4132
low Confidence
Subject:
radiation_therapy
(Treatment)
→
treats
→
Object:
locoregional_recurrence
(Disease phenotype)
Original: PLGAs#are associated with#multiple locoregional recurrences treated with excision and radiation therapy
#4131
low Confidence
Subject:
excision
(Treatment)
→
treats
→
Object:
locoregional_recurrence
(Disease phenotype)
Original: PLGAs#are associated with#multiple locoregional recurrences treated with excision and radiation therapy
#3433
low Confidence
Subject:
aspiration_cytology
(Cytological testing methods)
→
is_useful_for
→
Object:
treatment_of_hepatocellular_carcinoma_metastatic_to_nasal_cavity
(Disease treatment)
Original: aspiration cytology#is useful in#diagnosis and treatment of hepatocellular carcinoma metastatic to nasal cavity
#2613
low Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
right-sided_neck_dissection
(Surgery)
Original: Patient#underwent#inferior maxillectomy and right-sided neck dissection
#2612
low Confidence
Subject:
patient
(patient)
→
underwent
→
Object:
inferior_maxillectomy
(Surgery)
Original: Patient#underwent#inferior maxillectomy and right-sided neck dissection
#2412
low Confidence
Subject:
Surgical_excision
(Treatment)
→
was_performed_on
→
Object:
patient
(patient)
Original: Surgical excision#was performed#on the patient
#164
low Confidence
Subject:
PD-MSC_transplantation
(Cell therapy)
→
is_most_effective_treatment
→
Object:
HIE_at_day_7
(Disease phenotype)
Original: HIE + PD-MSC transplantation#was observed as#the most effective treatment at day 7
#15
low Confidence
Subject:
orchidectomy
(Surgery)
→
was_performed_on
→
Object:
patient
(patient)
Original: An orchidectomy and retroperitoneal biopsy#were performed#on the patient